No abstract

Trypanosomosis is a debilitating, fatal disease of man and animals often associated with anaemia. The trypanocides currently used in the management of the disease are far from giving desired results. This study investigated changes in haematological indices and the treatment outcome of diminazene aceturate (DA) against Trypanosoma brucei in dogs supplemented with resveratrol. A total of twenty (20) male Nigerian local breed of dogs (NBD) aged 6 to 12 months were used for the study. The dogs were randomly assigned into five groups (I-V) of four dogs per group. Group I was uninfected and unsupplemented; group II, was infected, untreated, and unsupplemented; group III, infected unsupplemented, treated with DA, group IV was infected and supplemented but untreated with DA, and group V was infected and supplemented DA-treated. The mean pre-patent period of Trypanosoma infection was 5.75±0.96 and 9.00±0.82 days for the infected unsupplemented and the infected resveratrol-supplemented groups, respectively. There was a complete parasite clearance from peripheral blood within 24-48 hours following treatment with DA on day 10 post-treatment (PT) in the supplemented and 24-72 hours in the unsupplemented treated groups. The supplemented treated did not show any relapse of infection, whereas the un-supplemented, DA-treated showed relapse on day 25 PT. It was concluded that resveratrol supplementation enhanced the efficacy of diminazene aceturate with no risk of relapse, minimized the effects of the parasite in the animals, and increased survival time.

This study was conducted to isolate enterococci from dogs in Nigeria, and to determine the potential virulence, antibiotic susceptibility, phenotypic vancomycin (VAN), high-level ampicillin (AMP) and aminoglycosides susceptibility profile of the isolates. Rectal swabs were collected from 295 randomly-selected, clinically-healthy dogs. The isolation of enterococci was done using Slanetz and Bartley enterococcal selective medium. The resistance of 150 non-repetitive isolates was determined using disc diffusion method. VAN resistance was assessed by high-level disc diffusion and agar-screening methods. High-level AMP and aminoglycosides (gentamicin and streptomycin) resistance was determined by agar-screening method. Potential virulence factors were assayed using phenotypic methods. Out of 295 samples, 234 (80.7%) gave positive growth. From these, 250 enterococcal isolates comprised 229 (91.6%) non-pigmented and 21 (8.4%) pigmented strains, were obtained. Resistance of the isolates was 89% to erythromycin, 92% to rifampicin, 77% to chloramphenicol, 83% to tetracycline, 64% to ciprofloxacin, 32.7% to VAN, 24.7% to high-level streptomycin (HLS) and 6% to high-level gentamicin (HLG). Among 150 non-repetitive resistant isolates, 144 (96%), including all the VAN-, HLS- and HLG-resistant strains, exhibited resistance to at least 3 classes of antibiotics. The mean multiple antibiotic resistance index was 0.54 (range = 0.22 – 0.89). Of these 150 isolates, 94 (62.7%), including all the VAN-, HLS- and HLG-resistant strains, displayed virulence potentials as biofilm (44.7%), surface-layer (13.8%), haemolysin (21.3%), gelatinase (40.4%), caesinase (10.6%) and deoxyribonuclease (12.8%) activities. This study showed that dogs in Nigeria are potential reservoirs and disseminators of potentially-virulent, multidrug-, VAN- and high-level aminoglycosides-resistant enterococci.